Isobutanoic acid

Synonyms: 异丁酸
Isobutanoic acid 是一种口服有效的 GPR41 和 GPR43 激动剂(pEC50 分别为 3.2-3.8 和 4.3-4.5),可有效抑制龈下致病菌,降低 FOXP3 mRNA 表达,激活 NF-κB (p-p65) 信号通路并提高 MMP-2 和 MMP-9 活性,还能结合 RACK1 以促进 Akt 和 FAK 信号通路,从而抑制癌细胞存活、激活 T 细胞并诱导凋亡 (apoptosis),同时也会促进结直肠癌转移以及诱导牙周软组织损伤和牙槽骨吸收,可用于结肠癌、口腔癌、牙周炎及结直肠癌转移的相关研究。
产品编号: MS-U82670 纯度: 99.75% CAS No.: 79-31-2 分子式: C4H8O2 分子量: 88.11
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
100mL
询价
3-5 天
250mL
询价
3-5 天
500mL
询价
询价
1L
询价
询价

产品描述

Isobutanoic acid 是一种口服有效的 GPR41 和 GPR43 激动剂(pEC50 分别为 3.2-3.8 和 4.3-4.5),可有效抑制龈下致病菌,降低 FOXP3 mRNA 表达,激活 NF-κB (p-p65) 信号通路并提高 MMP-2 和 MMP-9 活性,还能结合 RACK1 以促进 Akt 和 FAK 信号通路,从而抑制癌细胞存活、激活 T 细胞并诱导凋亡 (apoptosis),同时也会促进结直肠癌转移以及诱导牙周软组织损伤和牙槽骨吸收,可用于结肠癌、口腔癌、牙周炎及结直肠癌转移的相关研究。

生物实验数据

生物活性 Isobutanoic acid is an orally effective GPR41 and GPR43 agonist (pEC50 of 3.2-3.8 and 4.3-4.5, respectively) that effectively inhibits subgingival pathogens, reduces FOXP3 mRNA expression, activates the NF-κB (p-p65) signaling pathway, and increases MMP-2 and MMP-9 activity; it also binds RACK1 to promote Akt and FAK signaling pathways, thereby inhibiting cancer cell survival, activating T cells, and inducing apoptosis, while also promoting colorectal cancer metastasis and inducing periodontal soft tissue damage and alveolar bone resorption, and can be used for research related to colon cancer, oral cancer, periodontitis, and colorectal cancer metastasis.
IC50 & Target

Human Endogenous Metabolite

 

Microbial Metabolite

 

体外研究
(In Vitro)

Isobutyric acid (0.1-10 mM; 72 h) 在共培养体系中可优先抑制人口腔鳞状癌细胞系 T3M-1 Clone2 的存活,而对人 PBMC 来源的 T 细胞影响较小。
Isobutyric acid (0.1-10 mM; 72 h) 在共培养体系中优先抑制小鼠 CT-26 结肠癌细胞的存活,而非小鼠脾脏来源的 T 细胞,且其作用与 pH 变化无关。
Isobutyric acid (0.1-10 mM; 72 h) 可下调单培养的人 PBMC 来源 T 细胞中 FOXP3 的 mRNA 表达,同时上调 IFNG 和 PDCD1 的 mRNA 表达。
Isobutyric acid (100 μM) 可提高人牙周膜干细胞中磷酸化 NF-κB p65 的表达水平,并促进其向细胞核内聚集。
Isobutanoic acid (1 mM; 24 h) 可在 Transwell 实验中显著增强人结直肠癌 HCT116 和 SW48 细胞的迁移及侵袭活性。
Isobutanoic acid (1 mM; 24 h) 在人大肠癌细胞 HCT116 和 SW48 中可上调转移相关蛋白,并通过 RACK1 激活 AKT/FAK 信号通路,而 RACK1 敲低可逆转这些效应。

Cell Viability Assay

Cell Line: human T3M-1 Clone2 oral squamous carcinoma cells + human PBMC-derived T cells
Concentration: 0.1 mM, 3 mM, 10 mM
Incubation Time: 72 h
Result: Preferentially inhibited T3M-1 cancer cell survival over human T cell survival.
Significantly reduced T3M-1 cell numbers at 3 mM and 10 mM.
Had only minimal effects on human T cell numbers at 3 mM and 10 mM.
Reduced both CT-26 cancer cell and mouse T cell numbers in a concentration-dependent manner, with stronger effect on cancer cells.
Reduced CT-26 cell numbers by more than 60% at 10 mM.
Allowed over 60% of T cells to survive at 10 mM.

Real Time qPCR

Cell Line: human PBMC-derived T cells
Concentration: 0.1 mM, 3 mM, 10 mM
Incubation Time: 72 h
Result: Significantly decreased FOXP3 mRNA expression.
Significantly increased IFNG mRNA expression in a concentration-dependent manner.
Significantly upregulated PDCD1 mRNA expression.
Upregulated ICOS mRNA at higher concentrations, though not significantly.

Western Blot Analysis

Cell Line: human periodontal ligament stem cells (hPDLSCs)
Concentration: 50 μM, 100 μM, 200 μM
Incubation Time: 6 h
Result: Increased p-p65 protein expression in a dose-dependent manner.
Raised p-p65 expression 2.5-fold relative to β-actin at 100 μM and 2.3-fold relative to β-actin at 200 μM.
Caused no consistent or statistically significant changes in phosphorylation levels of ERK, p38, and JNK.

Western Blot Analysis

Cell Line: RACK1-knockdown human colorectal cancer HCT116 and SW48 cells
Concentration: 1 mM
Incubation Time: 24 h
Result: Reversed the isobutanoic acid-induced upregulation of ICAM1, MMP2, MMP9, p-AKT, and p-FAK protein levels in both HCT116 and SW48 cells.
Left total AKT and FAK protein levels unchanged across all groups.
体内研究
(In Vivo)

Isobutyric acid (100 mM;口服;每日;接种前给药 2 周并持续至接种后) 可在小鼠结肠癌模型中增强抗 PD-1 抗体的抗肿瘤功效,显著抑制肿瘤生长、增加肿瘤浸润 T 细胞数量,并上调肿瘤组织中促免疫基因的表达。
Isobutanoic acid (5 mM;局部注射;每周 3 次;持续 4 周) 可诱导大鼠牙周组织损伤及牙槽骨吸收,同时其 MMP-2、MMP-9 和 NF-κB (p-p65) 的表达水平较对照组升高 3 倍。
Isobutanoic acid (200 mM;口服;持续给药;8 周以上) 可促进 BALB/c 裸鼠体内结直肠癌肝转移,增加转移结节数量并降低总生存期,同时上调转移相关蛋白的表达。
Isobutanoic acid (200 mM;口服;持续给药;8 周以上) 可促进 BALB/c 裸鼠的结直肠癌肺转移,增加转移结节数量并降低总生存期,同时上调转移相关蛋白的表达。
Isobutanoic acid (200 mM;口服;持续给药;8 周) 在 BALB/c 裸鼠中诱导的结直肠癌肝转移由 RACK1 介导,因为敲低 RACK1 可消除异丁酸的促转移作用。
Isobutanoic acid (200 mM;口服;持续给药;8 周) 诱导 BALB/c 裸小鼠发生结直肠癌肺转移的作用由 RACK1 介导,因为敲低 RACK1 可消除异丁酸的促转移效应。

Animal Model: BALB/C (8-12-week-old male; subcutaneous injection of 2 × 105 CT26 colon cancer cells into the right flank)
Dosage: 100 mM
Administration: p.o.; daily; 2 weeks pre-inoculation and continued post-inoculation
Result: Significantly suppressed tumour growth compared to control, anti-PD-1 monotherapy, or isobutyric acid monotherapy groups.
Increased the density of tumour-infiltrating CD3+ T cells to 1600 counts/mm2.
Significantly upregulated tumour tissue mRNA expression of IFNG, ICOS, and PDCD1.
Achieved higher objective response rate (complete response plus partial response rates) than anti-PD-1 monotherapy.
Reduced tumour volumes in non-responder mice substantially compared to those receiving anti-PD-1 alone.
Animal Model: Sprague-Dawley (5-week-old male, periodontitis model via local injection into palatal mesial and distal alveolar bone crest of maxillary second molar)
Dosage: 5 mM
Administration: local injection; three times per week; 4 weeks
Result: Increased average alveolar bone loss to ~0.75 mm, compared to ~0.4 mm in controls.
Reduced average bone volume/tissue volume ratio to ~30%, compared to ~75% in controls.
Increased average trabecular separation to ~0.13 mm, compared to ~0.04 mm in controls.
Increased MMP-2 expression to ~3-fold relative to controls.
Increased MMP-9 expression to ~3-fold relative to controls.
Increased NF-kB (p-p65) expression to ~3-fold relative to controls, with notable nuclear accumulation in periodontal tissues.
性状 液体(密度:0.95 g/cm3)
颜色 Colorless to light yellow

化学信息

分子量 88.11
分子式 C4H8O2
CAS No. 79-31-2
别名 异丁酸

储存&溶解度

储存方式
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 35 mg/mL (397.23 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM11.3494 mL56.7472 mL113.4945 mL283.7362 mL
5 mM2.2699 mL11.3494 mL22.6989 mL56.7472 mL
10 mM1.1349 mL5.6747 mL11.3494 mL28.3736 mL
15 mM0.7566 mL3.7831 mL7.5663 mL18.9157 mL
20 mM0.5675 mL2.8374 mL5.6747 mL14.1868 mL
25 mM0.4540 mL2.2699 mL4.5398 mL11.3494 mL
30 mM0.3783 mL1.8916 mL3.7831 mL9.4579 mL
40 mM0.2837 mL1.4187 mL2.8374 mL7.0934 mL
50 mM0.2270 mL1.1349 mL2.2699 mL5.6747 mL
60 mM0.1892 mL0.9458 mL1.8916 mL4.7289 mL
80 mM0.1419 mL0.7093 mL1.4187 mL3.5467 mL
100 mM0.1135 mL0.5675 mL1.1349 mL2.8374 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础